Ring Energy Announces Production Results and Continued Debt Reduction for Fourth Quarter 2023 and Partial Guidance for the First Quarter 2024
~ Record Q4 2023 Sales Volumes Near High End of Guidance ~ ~ Further Reduced Debt in Addition to Making […]
Oculis to Present at Upcoming February Investor Conferences
ZUG, Switzerland and BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company […]
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for […]
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing […]
WillScot Mobile Mini to Acquire McGrath RentCorp for $3.8 Billion, Enhancing Its Position as the North American Leader in Turnkey Space Solutions
60% Cash and 40% Stock Transaction Provides McGrath RentCorp Shareholders with $123 Per Share and Upside through Approximately 12.6% Stake […]
Provident Financial Holdings Reports Second Quarter Fiscal Year 2024 Results
Net Income of $2.14 Million in the December 2023 Quarter Net Interest Margin of 2.78% in the December 2023 Quarter […]
Coda Octopus Group Reports Fiscal 2023 Financial Results
ORLANDO, FL, Jan. 29, 2024 (GLOBE NEWSWIRE) — Coda Octopus Group, Inc. (CODA) (Nasdaq: CODA) today reported its audited financial […]
Gamida Cell Actively Pursuing Strategic Alternatives
BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) — Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells […]
Comstock Inc. to Present at the Battery & Precious Metals Virtual Investor Conference on January 30, 2024
Comstock invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com VIRGINIA CITY, Nev., […]
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its […]
